RARA and acute myeloid leukemia: For example, some AML patients may benefit from antagonism of all RARs because leukemogenesis was delayed and stemness was reduced in an Evi1high and MA-9 driven mouse model of AML by the pan-RAR antagonist AGN193109 [61].